SCHEMBL740827

SCHEMBL740827

COc1ccccc1C(C)(C)NC(=O)c1cc2c(NC(=O)c3ccc(CN4CCOCC4)cc3)n[nH]c2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.51
BCR P11274 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 3/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
KDR P35968 2/20 0.45
KMT2A Q03164 1/20 0.44
HIF1A Q16665 2/20 0.44
EPAS1 Q99814 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 2/20 0.43
HPGD P15428 2/20 0.42
FGFR1 P11362 1/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPK14 Q16539 1/20 0.42
AURKA O14965 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742316 0.93 ABL1 (0.57) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL740797 0.93 ABL1 (0.59) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL740545 0.93 ABL1 (0.60) ABL1BCRSMN1; SMN2LMNATP53
SCHEMBL740144 0.90 ABL1 (0.52) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL742155 0.90 FGFR1 (0.51) ABL1BCRKDRKMT2AALDH1A1
SCHEMBL742258 0.89 ABL1 (0.65) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL740986 0.88 ABL1 (0.54) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL739902 0.87 LMNA (0.54) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL739685 0.87 ABL1 (0.56) ABL1BCRSMN1; SMN2LMNARAB9A
SCHEMBL1779566 0.84 ABL1 (0.59) ABL1BCRSMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US claimed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed